Calliditas Therapeutics AB (publ) CALT
40.00 +40.00
Day range unavailable
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 39.25 -1.9% downside
Now 40.00
- Target (low)
- 39.00
- Target (mean)
- 39.25
- Target (high)
- 40.00
Ratings (-1m) 6 0 buy · 6 hold · 0 sell
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 6
- 2 months ago 6
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.22 | -0.22 – -0.22 | -0.58 | +62.1% | 57.11M | +102.0% | 1 |
| Next quarter | -0.04 | -0.04 – -0.04 | -0.06 | +33.3% | 60.02M | +41.5% | 1 |
| Current year | -1.29 | -1.29 – -1.29 | -1.64 | +21.3% | 198.91M | +74.8% | 1 |
| Next year | 6.32 | 6.32 – 6.32 | -1.29 | +589.9% | 337.55M | +69.7% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 20, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 17, 2023 | Guggenheim | Maintained | Neutral | Neutral |
| Jun 19, 2023 | HC Wainwright & Co. | Initiated | — | Buy |
| Feb 28, 2023 | Guggenheim | Initiated | — | Neutral |
| Feb 23, 2023 | Citigroup | Maintained | — | Buy |
| Dec 19, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Jun 29, 2020 | Jefferies | Initiated | — | Buy |
| Jun 29, 2020 | Stifel | Initiated | — | Buy |